Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type TP53 status confers therapeutic sensitivity to Venetoclax in patients with Chronic Lymphocytic Leukemia.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor